Novo Nordisk shared findings from the US-based INFORM survey during the European Association for the Study of Diabetes (EASD) 2025 in Vienna, Austria. The survey focused on individuals using semaglutide for weight management (Wegovy ® ), showing a significant decrease in food noise, defined as unwanted thoughts about food, following the start of Wegovy ® treatment. This reduction in food noise was accompanied by improvements in mental well-being and lifestyle for participants. The survey highlighted the impact of food noise on the quality of life, weight loss efforts, and mental health of individuals dealing with overweight or obesity.